Reinforcement learning as an intermediate phenotype in psychosis? Deficits sensitive to illness stage but not associated with polygenic risk of schizophrenia in the general population.
Bayesian
Computational psychiatry
Go/NoGo task
PRS
Psychosis
Reinforcement learning
Schizophrenia
Journal
Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
11
06
2019
revised:
20
01
2020
accepted:
19
04
2020
pubmed:
12
5
2020
medline:
22
6
2021
entrez:
12
5
2020
Statut:
ppublish
Résumé
Schizophrenia is a complex disorder in which the causal relations between risk genes and observed clinical symptoms are not well understood and the explanatory gap is too wide to be clarified without considering an intermediary level. Thus, we aimed to test the hypothesis of a pathway from molecular polygenic influence to clinical presentation occurring via deficits in reinforcement learning. We administered a reinforcement learning task (Go/NoGo) that measures reinforcement learning and the effect of Pavlovian bias on decision making. We modelled the behavioural data with a hierarchical Bayesian approach (hBayesDM) to decompose task performance into its underlying learning mechanisms. Study 1 included controls (n = 29, F|M = 0.81), At Risk Mental State for psychosis (ARMS, n = 23, F|M = 0.35) and FEP (First-episode psychosis, n = 26, F|M = 0.18). Study 2 included healthy adolescents (n = 735, F|M = 1.06), 390 of whom had their polygenic risk scores for schizophrenia (PRSs) calculated. Patients with FEP showed significant impairments in overriding Pavlovian conflict, a lower learning rate and a lower sensitivity to both reward and punishment. Less widespread deficits were observed in ARMS. PRSs did not significantly predict performance on the task in the general population, which only partially correlated with measures of psychopathology. Reinforcement learning deficits are observed in first episode psychosis and, to some extent, in those at clinical risk for psychosis, and were not predicted by molecular genetic risk for schizophrenia in healthy individuals. The study does not support the role of reinforcement learning as an intermediate phenotype in psychosis.
Sections du résumé
BACKGROUND
Schizophrenia is a complex disorder in which the causal relations between risk genes and observed clinical symptoms are not well understood and the explanatory gap is too wide to be clarified without considering an intermediary level. Thus, we aimed to test the hypothesis of a pathway from molecular polygenic influence to clinical presentation occurring via deficits in reinforcement learning.
METHODS
We administered a reinforcement learning task (Go/NoGo) that measures reinforcement learning and the effect of Pavlovian bias on decision making. We modelled the behavioural data with a hierarchical Bayesian approach (hBayesDM) to decompose task performance into its underlying learning mechanisms. Study 1 included controls (n = 29, F|M = 0.81), At Risk Mental State for psychosis (ARMS, n = 23, F|M = 0.35) and FEP (First-episode psychosis, n = 26, F|M = 0.18). Study 2 included healthy adolescents (n = 735, F|M = 1.06), 390 of whom had their polygenic risk scores for schizophrenia (PRSs) calculated.
RESULTS
Patients with FEP showed significant impairments in overriding Pavlovian conflict, a lower learning rate and a lower sensitivity to both reward and punishment. Less widespread deficits were observed in ARMS. PRSs did not significantly predict performance on the task in the general population, which only partially correlated with measures of psychopathology.
CONCLUSIONS
Reinforcement learning deficits are observed in first episode psychosis and, to some extent, in those at clinical risk for psychosis, and were not predicted by molecular genetic risk for schizophrenia in healthy individuals. The study does not support the role of reinforcement learning as an intermediate phenotype in psychosis.
Identifiants
pubmed: 32389614
pii: S0920-9964(20)30229-2
doi: 10.1016/j.schres.2020.04.022
pmc: PMC7594641
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
389-396Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_G0802534
Pays : United Kingdom
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Front Psychiatry. 2013 Dec 23;4:172
pubmed: 24391603
Neuroimage. 2012 Aug 1;62(1):154-66
pubmed: 22548809
Neuropsychopharmacology. 2018 Jul;43(8):1691-1699
pubmed: 29748629
Arch Gen Psychiatry. 2012 Feb;69(2):129-38
pubmed: 22310503
PLoS One. 2016 Apr 04;11(4):e0152781
pubmed: 27044008
Int J Epidemiol. 2018 Feb 1;47(1):18-19g
pubmed: 29177462
Br J Psychiatry. 1995 Jul;167(1):99-103
pubmed: 7551619
Brain. 2016 Oct;139(Pt 10):2600-2608
pubmed: 27543973
Mol Psychiatry. 2008 Mar;13(3):239, 267-76
pubmed: 17684497
Brain. 2019 Feb 1;142(2):471-485
pubmed: 30535067
BMJ. 2012 Apr 05;344:e2233
pubmed: 22491790
Schizophr Bull. 2016 Nov;42(6):1476-1485
pubmed: 27179125
J Neurophysiol. 2015 Jun 1;113(10):3459-61
pubmed: 25185818
Schizophr Res. 2008 Sep;104(1-3):279-86
pubmed: 18562177
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9105-10
pubmed: 27457931
Comput Psychiatr. 2017 Oct 01;1:24-57
pubmed: 29601060
JAMA Psychiatry. 2016 Mar;73(3):221-8
pubmed: 26818099
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
PLoS Biol. 2016 Nov 10;14(11):e2000638
pubmed: 27832071
Psychol Aging. 2016 Nov;31(7):747-757
pubmed: 27599017
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
PLoS Comput Biol. 2018 Dec 31;14(12):e1006679
pubmed: 30596638
Schizophr Bull. 2008 Sep;34(5):835-47
pubmed: 18591195
Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Nov;2(8):680-688
pubmed: 29560902
JAMA Psychiatry. 2016 Aug 1;73(8):852-61
pubmed: 27384424
Schizophr Bull. 1991;17(4):555-64
pubmed: 1805349
JAMA Psychiatry. 2014 May;71(5):531-9
pubmed: 24622944
Psychol Med. 2018 Aug;48(11):1909-1914
pubmed: 29233195
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
Nat Genet. 2018 Mar;50(3):381-389
pubmed: 29483656
Nat Rev Neurosci. 2015 May;16(5):278-89
pubmed: 25873038
Schizophr Bull. 2019 Mar 7;45(2):405-414
pubmed: 29608775
Schizophr Bull. 2004;30(4):1005-22
pubmed: 15954204
Nature. 2009 Aug 6;460(7256):748-52
pubmed: 19571811
Biol Psychiatry. 2000 Feb 1;47(3):210-20
pubmed: 10682218
J Am Acad Child Adolesc Psychiatry. 1988 Nov;27(6):726-37
pubmed: 3058677
Schizophr Bull. 2008 Nov;34(6):1008-11
pubmed: 18791075
Cogn Behav Neurol. 2004 Mar;17(1):32-40
pubmed: 15209223
Psychol Med. 2018 Jan;48(2):327-336
pubmed: 28641601